公开(公告)号：US20240308995A1

公开(公告)日：2024-09-19

申请号：US18673619

申请日：2024-05-24

Applicant: BIOGEN MA INC.

Inventor： Nathan Genung ,  Kevin M. Guckian ,  Jeffrey Vessels ,  Lei Zhang ,  Ryan Gianatassio ,  Edward Yin Shiang Lin ,  Zhili Xin

IPC: C07D417/14 ,  A61P25/28 ,  C07D417/06

CPC classification number: C07D417/14 ,  A61P25/28 ,  C07D417/06

Abstract: Described herein are compounds represented by formulas (IA) or (IB)




or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of preparing and using the same. The variables R1, R3, R4, Y1, Y2, Ar, Z and n are as defined herein.

公开(公告)号：US20210340107A1

公开(公告)日：2021-11-04

申请号：US17221358

申请日：2021-04-02

Applicant: BIOGEN MA INC.

Inventor： Brian Stuart Lucas ,  Edward Yin Shiang Lin ,  Andrew George Capacci ,  Zhili Xin ,  Istvan Enyedy ,  TeYu Chen ,  John H. Jones ,  Kurt D. van Vloten

IPC: C07D217/04 ,  C07D217/08 ,  C07D217/20 ,  C07D217/22 ,  C07D223/14 ,  C07D311/74 ,  C07D401/04 ,  C07D401/06 ,  C07D405/04 ,  C07D405/06 ,  C07D413/06 ,  C07D498/04

Abstract: Provided are compounds of Formula I, or pharmaceutically acceptable salts thereof, and methods for their use and production.

公开(公告)号：US20250152574A1

公开(公告)日：2025-05-15

申请号：US18837245

申请日：2023-02-13

Applicant: BIOGEN MA INC.

Inventor： Martin Himmelbauer ,  Felix Gonzalez Lopez de Turiso ,  John H. Jones ,  Edward Yin Shiang Lin ,  Robin Prince ,  Vatee Pattaropong ,  Zhili Xin ,  TeYu Chen ,  Nupur Bansal

IPC: A61K31/4709 ,  A61K31/438 ,  A61P25/28 ,  C07D221/20 ,  C07D401/12 ,  C07D491/107

Abstract: Provided are compounds of the Formula (I) or pharmaceutically acceptable salts thereof, which are useful for the inhibition of EBP and in the treatment of a variety of EBP mediated conditions or diseases, such as multiple sclerosis.

公开(公告)号：US20220259197A1

公开(公告)日：2022-08-18

申请号：US17435125

申请日：2020-03-06

Applicant: BIOGEN MA INC.

Inventor： Nathan Genung ,  Kevin M. Guckian ,  Jeffrey Vessels ,  Lei Zhang ,  Ryan Gianatassio ,  Edward Yin Shiang Lin ,  Zhili Xin

IPC: C07D417/14 ,  C07D495/04

Abstract: Described herein are compounds represented by formula (I) (I) or a pharmaceutically acceptable salt thereof, pharmaceutical comositions comprising the same and methods of preparing and using the same. The variables Ar, X, R1, R3, R4, Y1, Y2, and Z are as defined herein.

公开(公告)号：US20210040080A1

公开(公告)日：2021-02-11

申请号：US16978550

申请日：2019-03-13

Applicant: BIOGEN MA INC.

Inventor： Nathan Genung ,  Kevin M. Guckian ,  Jeffrey Vessels ,  Lei Zhang ,  Ryan Gianatassio ,  Edward Yin Shiang Lin ,  Zhili Xin

IPC: C07D417/14 ,  C07D471/04 ,  C07D417/06

Abstract: Described herein are compounds represented by formula (I″) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of preparing and using the same. The variables Ar, Ra, Rb, m, n, Y1, Y2, R3 and R4 are defined herein.

公开(公告)号：US12275728B2

公开(公告)日：2025-04-15

申请号：US18673619

申请日：2024-05-24

Applicant: BIOGEN MA INC.

Inventor： Nathan Genung ,  Kevin M. Guckian ,  Jeffrey Vessels ,  Lei Zhang ,  Ryan Gianatassio ,  Edward Yin Shiang Lin ,  Zhili Xin

IPC: C07D417/14 ,  A61P25/28 ,  C07D417/06

Abstract: Described herein are compounds represented by formulas (IA) or (IB) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of preparing and using the same. The variables R1, R3, R4, Y1, Y2, Ar, Z and n are as defined herein.

公开(公告)号：US20250090524A1

公开(公告)日：2025-03-20

申请号：US18709268

申请日：2022-11-11

Applicant: BIOGEN MA INC.

Inventor： Brian T. Hopkins ,  BIn Ma ,  Jürgen Schulz ,  Marta Nevalainen ,  TeYu Chen ,  Robin J. Prince ,  Harold George Vandeveer ,  Issac Marx ,  Simone Sciaboba ,  Edward Yin Shiang Lin

IPC: A61K31/4985 ,  A61K31/437 ,  A61K31/55 ,  C07D471/04 ,  C07D487/04

Abstract: Provided are compounds of Formula (I) or pharmaceutically acceptable salts thereof, wherein the variables in Formula (I) are as defined herein; and methods for their use and production.

公开(公告)号：US20240327380A1

公开(公告)日：2024-10-03

申请号：US18019540

申请日：2021-08-05

Applicant: BIOGEN MA INC.

Inventor： Brian T. Hopkins ,  Isaac Marx ,  Jürgen Schulz ,  Harold George Vandeveer ,  Robin Prince ,  Marta Nevalainen ,  TeYu Chen ,  Zain Yousaf ,  Martin Himmelbauer ,  Vatee Pattaropong ,  John Howard Jones ,  Rab Gilfillan ,  Edward Yin Shiang Lin ,  Felix Gonzalez Lopez de Turiso ,  Bin Ma

IPC: C07D401/14 ,  A61K31/4439 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/55 ,  A61K31/553 ,  C07D401/12 ,  C07D403/12 ,  C07D413/12 ,  C07D413/14 ,  C07D471/04 ,  C07D471/08 ,  C07D487/10

CPC classification number: C07D401/14 ,  A61K31/4439 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/55 ,  A61K31/553 ,  C07D401/12 ,  C07D403/12 ,  C07D413/12 ,  C07D413/14 ,  C07D471/04 ,  C07D471/08 ,  C07D487/10

Abstract: Provided are compounds of Formula (I): or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R7, R8, R9, A1, A2, Q1, Q2, Q3, A, Z, m and n are as defined herein; pharmaceutical compositions comprising said compounds or pharmaceutically acceptable salts thereof, and pharmaceutically acceptable excipients; and methods of treating a disorder responsive to inhibition of Bruton's tyrosine kinase using said compounds, or pharmaceutically acceptable salts thereof, or said pharmaceutical compositions.

公开(公告)号：US11459324B2

公开(公告)日：2022-10-04

申请号：US16978550

申请日：2019-03-13

Applicant: BIOGEN MA INC.

Inventor： Nathan Genung ,  Kevin M. Guckian ,  Jeffrey Vessels ,  Lei Zhang ,  Ryan Gianatassio ,  Edward Yin Shiang Lin ,  Zhili Xin

IPC: C07D417/14 ,  C07D417/06 ,  C07D471/04

Abstract: Described herein are compounds represented by formula (I″) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of preparing and using the same. The variables Ar, Ra, Rb, m, n, Y1, Y2, R3 and R4 are defined herein.

公开(公告)号：US20210387960A1

公开(公告)日：2021-12-16

申请号：US17333498

申请日：2021-05-28

Applicant: BIOGEN MA INC.

Inventor： Andrew George Capacci ,  Edward Yin Shiang Lin ,  Brian Stuart Lucas

IPC: C07D311/74

Abstract: Provided are compounds of Formula I, or pharmaceutically acceptable salts thereof, which are activators of nuclear factor erythroid 2 (NF-E2)-related factor 2 (Nrf2) and are useful to treat diseases caused by oxidative stress, such as neurodegenerative diseases or inflammation. Also provided are methods for their use and production.